Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Lode · SciRah

Researcher profile · Semantic Scholar

H. Lode

Share profile

H. Lode — researcher profile on SciRah

h-index: 42
Works: 214
Citations: 5,580

Most-cited papers

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
R. Ladenstein, U. Pötschger, D. Valteau-Couanet, R. Luksch +20 more
2018The Lancet Oncology341 citations
Semantic Scholar
Mutational dynamics between primary and relapse neuroblastomas
A. Schramm, J. Köster, Y. Assenov, K. Althoff +31 more
2015Nature Genetics310 citations
Semantic Scholar
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
R. Ladenstein, U. Pötschger, D. Valteau-Couanet, R. Luksch +20 more
2020Cancers153 citations Open access
Semantic Scholar
2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors
T. Simon, B. Hero, J. Schulte, H. Deubzer +14 more
2017Klinische Pädiatrie110 citations
Semantic Scholar
EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells.
S. Kailayangiri, B. Altvater, S. Lesch, S. Balbach +16 more
2019Molecular Therapy103 citations Open access
Semantic Scholar
Chronic diseases in pregnant women: prevalence and birth outcomes based on the SNiP-study
I. Kersten, A. Lange, J. Haas, C. Fusch +3 more
2014BMC Pregnancy and Childbirth101 citations Open access
Semantic Scholar
Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO
Ina Mueller, K. Ehlert, S. Endres, L. Pill +13 more
2017mAbs80 citations Open access
Semantic Scholar
Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma
M. Lodrini, A. Sprüssel, K. Astrahantseff, Daniela Tiburtius +6 more
2017OncoTarget73 citations Open access
Semantic Scholar
Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma.
Toni Illhardt, J. Toporski, T. Feuchtinger, D. Turkiewicz +13 more
2018Biology of Blood and Marrow Transplantation65 citations Open access
Semantic Scholar
GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18
W. Glienke, A. Dragon, Katharina Zimmermann, A. Martyniszyn-Eiben +17 more
2022Frontiers in Immunology61 citations Open access
Semantic Scholar
PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO
N. Siebert, M. Zumpe, Madlen Jüttner, S. Troschke-Meurer +1 more
2017Oncoimmunology61 citations Open access
Semantic Scholar
Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma.
E. Berger, R. Soldati, N. Huebener, O. Hohn +7 more
2013Cancer Letters58 citations
Semantic Scholar
Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival
N. Siebert, C. Jensen, S. Troschke-Meurer, M. Zumpe +5 more
2016Oncoimmunology57 citations Open access
Semantic Scholar
Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2
N. Siebert, Christin Eger, D. Seidel, Madlen Jüttner +10 more
2016mAbs56 citations Open access
Semantic Scholar
Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response
H. Lode, M. Schmidt, D. Seidel, N. Huebener +7 more
2013Cancer Immunology and Immunotherapy54 citations
Semantic Scholar
Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
K. Ehlert, Ina Hansjuergens, A. Zinke, S. Otto +3 more
2020Journal for ImmunoTherapy of Cancer53 citations Open access
Semantic Scholar
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial
T. Flaadt, R. Ladenstein, M. Ebinger, H. Lode +23 more
2023Journal of Clinical Oncology52 citations Open access
Semantic Scholar
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells
A. Tivnan, Tatjana Heilinger, Joanne M. Ramsey, Gemma O’Connor +9 more
2017OncoTarget41 citations Open access
Semantic Scholar
Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma
D. Seidel, Anastasia Shibina, N. Siebert, W. Wels +3 more
2015Cancer Immunology and Immunotherapy41 citations
Semantic Scholar
Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
A. Wieczorek, Anna Zaniewska-Tekieli, K. Ehlert, K. Pawińska-Wąsikowska +2 more
2023Frontiers in Oncology32 citations Open access
Semantic Scholar
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
H. Lode, K. Ehlert, S. Huber, S. Troschke-Meurer +4 more
2023British Journal of Cancer31 citations Open access
Semantic Scholar
Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front–line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.
R. Ladenstein, U. Poetschger, D. Valteau-Couanet, Juliet C. Gray +16 more
2019Journal of Clinical Oncology29 citations
Semantic Scholar
In vitro response of THP-1 derived macrophages to antimicrobially effective PHMB-coated Ti6Al4V alloy implant material with and without contamination with S. epidermidis and P. aeruginosa
P. Zwicker, Thomas Schmidt, M. Hornschuh, H. Lode +2 more
2022Biomaterials Research27 citations Open access
Semantic Scholar
Targeting of heme oxygenase‐1 as a novel immune regulator of neuroblastoma
S. Fest, R. Soldati, N. Christiansen, Maria Laura Zenclussen +7 more
2016International Journal of Cancer27 citations Open access
Semantic Scholar
Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody
N. Siebert, D. Seidel, Christin Eger, Madlen Jüttner +1 more
2014PLoS ONE27 citations Open access
Semantic Scholar
Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells
C. Riess, Katharina del Moral, Adina Fiebig, P. Kaps +12 more
2022Cell Death and Disease25 citations Open access
Semantic Scholar
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma
Sascha Marx, Fabian Wilken, I. Wagner, M. Marx +10 more
2020Journal of Neuro-Oncology23 citations
Semantic Scholar
Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.
H. Lode, D. Valteau-Couanet, Juliet C. Gray, R. Luksch +13 more
2019Journal of Clinical Oncology22 citations
Semantic Scholar
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
N. Siebert, S. Troschke-Meurer, M. Marx, M. Zumpe +12 more
2018Cancers22 citations Open access
Semantic Scholar
Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
A. Wieczorek, C. Manzitti, A. Garaventa, Juliet C. Gray +8 more
2022Cancers21 citations Open access
Semantic Scholar
Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice
A. Stermann, N. Huebener, D. Seidel, S. Fest +5 more
2015Cancer Immunology and Immunotherapy20 citations
Semantic Scholar
Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2
S. Troschke-Meurer, N. Siebert, M. Marx, M. Zumpe +5 more
2019Oncoimmunology19 citations Open access
Semantic Scholar
Toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: Final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial).
R. Ladenstein, U. Poetschger, Juliet C. Gray, D. Valteau-Couanet +16 more
201619 citations
Semantic Scholar
Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
N. Siebert, M. Zumpe, Christian Heinrich Schwencke, Simon Biskupski +4 more
2023Cancers18 citations Open access
Semantic Scholar
Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
C. Seitz, T. Flaadt, Markus Mezger, Anne-Marie Lang +17 more
2021Frontiers in Immunology18 citations Open access
Semantic Scholar
Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
S. Troschke-Meurer, M. Zumpe, Lena Meißner, N. Siebert +5 more
2023Cancers17 citations Open access
Semantic Scholar
Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
N. Siebert, Christin Eger, D. Seidel, Madlen Jüttner +1 more
2014JIM - Journal of Immunological Methods17 citations
Semantic Scholar
First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma
Neofit Spasov, F. Dombrowski, H. Lode, M. Spasova +4 more
2022Journal of pediatric hematology/oncology15 citations Open access
Semantic Scholar
Inflammatory response and treatment tolerance of long‐term infusion of the anti‐GD2 antibody ch14.18/CHO in combination with interleukin‐2 in patients with high‐risk neuroblastoma
K. Ceylan, Luciana J. Jahns, Bjoern N Lode, K. Ehlert +4 more
2018Pediatric Blood & Cancer15 citations
Semantic Scholar
Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma
Christin Eger, N. Siebert, D. Seidel, M. Zumpe +4 more
2016PLoS ONE15 citations Open access
Semantic Scholar
GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
F. Zirngibl, S. M. Ivasko, Laura Grunewald, Anika Klaus +11 more
2021Journal for ImmunoTherapy of Cancer14 citations Open access
Semantic Scholar
Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma.
P. Lang, Toni Illhardt, M. Ebinger, P. Schlegel +9 more
201514 citations
Semantic Scholar
Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory neuroblastoma patients.
H. Lode, D. Valteau-Couanet, A. Garaventa, Juliet C. Gray +15 more
201512 citations
Semantic Scholar
Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
H. Lode, R. Ladenstein, S. Troschke-Meurer, Linda Struppe +10 more
2023Cancers11 citations Open access
Semantic Scholar
Triage through telemedicine in paediatric emergency care—Results of a concordance study
A. Beyer, K. Moon, Peter Penndorf, T. Hirsch +4 more
2022PLoS ONE11 citations Open access
Semantic Scholar
Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma
Felix Schriegel, S. Taschner-Mandl, M. Bernkopf, U. Grunwald +6 more
2021Journal of Cancer Research and Clinical Oncology11 citations Open access
Semantic Scholar
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Filiz Çiçek, S. Troschke-Meurer, K. Ceylan, Luciana J. Jahns +4 more
2020Frontiers in Pediatrics11 citations Open access
Semantic Scholar
Spontaneous vesicoureteral reflux resolution in children: A ten-year single-centre experience
P. Wildbrett, M. Schwebs, J. Abel, H. Lode +1 more
2013African Journal of Paediatric Surgery11 citations Open access
Semantic Scholar
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments
Leah Klingel, N. Siebert, S. Troschke-Meurer, M. Zumpe +5 more
2022Cancers10 citations Open access
Semantic Scholar
The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta
N. Siebert, Justus Leopold, M. Zumpe, S. Troschke-Meurer +3 more
2022Cancers10 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Siebert×28
Invite
N. Siebert — researcher profile on SciRah
S. Troschke-Meurer×16
Invite
S. Troschke-Meurer — researcher profile on SciRah
M. Zumpe×15
Invite
M. Zumpe — researcher profile on SciRah
R. Ladenstein×14
Invite
R. Ladenstein — researcher profile on SciRah

×14

Invite

K. Ehlert — researcher profile on SciRah

Invite

H. Loibner — researcher profile on SciRah

D. Valteau-Couanet×9

Invite

D. Valteau-Couanet — researcher profile on SciRah

Invite

D. Seidel — researcher profile on SciRah

Invite

V. Castel — researcher profile on SciRah

A. Garaventa×7

Invite

A. Garaventa — researcher profile on SciRah

Invite

A. Eggert — researcher profile on SciRah

Madlen Jüttner×6

Invite

Madlen Jüttner — researcher profile on SciRah